We are honored to support groundbreaking discoveries related to Dystroglycanopathy.

We are honored to support groundbreaking discoveries related to LAMA2-Related Dystrophy.

Join a newly forming council to help direct legislative priorities for the CMD community.

I had the opportunity to kick off my rare advocacy journey and experience my first Capitol Hill Day.

The MAGIC research team welcomes iMM to the consortium to add a cellular perspective to muscle-on-chip technologies

Long-awaited publication about the Phase 1 Open-Label Study of Omigapil in Patients With LAMA2- or COL6-Related Dystrophy now published.

We are honored to support groundbreaking discoveries related to SELENON-Related Disorders.

Explore an in-depth interview with Gustavo Dziewczapolski, Doctor in Neuropharmacology and Scientific Director of Cure CMD. Gain insights in

Cure CMD’s Scientific Director, Dr. Gustavo Dziewczapolski, provides a recap of his attendance at the 8th International Myology Congress in

We are honored to support groundbreaking discoveries in Collagen 6-Related Dystrophies (COL6-RD).

Honoring community member Simon Cantos and his legacy in the congenital muscular dystrophy community.

My rare disease advocacy journey started later in life. Like many, I had always felt too overwhelmed and unsure of how to start and was...